Pneumococcal Meningitis – According to the report analysis, ‘Pneumococcal Meningitis Global Clinical Trials Review, H1, 2018’ suggests that some of the major companies and health care centers are working actively with more upgradation in the technology and research programs which includes Pfizer Inc, GlaxoSmithKline Plc, BIOVOMED, Novartis AG, Merck & Co Inc, UCB SA Syneos Health Inc, InVentiv Group Holdings, Inc., Baxter International Inc, Abbott Laboratories, Daiichi Snankyo Company, Ltd., GE Healthcare, Biogen Idec Inc., Hoffmann-La Roche Ltd., Celegene Corporation, Johnson & Johnson, Eli Lilly and Company, Bristol-Myers Squibb Company, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, Ohio State University, University of Pennsylvania, Case Comprehensive Cancer Center, Mayo Clinic, Duke University and others. Moreover, growing government and non-government funding for development of vaccine, prevalence of disease and significant increase in the research and development has been driving the vaccines market.
Meninges are the membranes that cover the spinal cord and brain and meningitis is an infection of the meninges. The infection of the meninges can be caused by fungi, parasites, bacteria, viruses and others. However, pneumococcal meningitis is a bacterial form of meningitis. Pneumococcal meningitis is a very serious disease that can be cause death even with the proper treatment. The symptoms of Pneumococcal Meningitis is typically develop in one to three days after the exposed to the bacteria whereas, in many cases the symptoms may develop sooner and later as the case may be. Chest pain, confusion, agitation, vomiting, stiff neck, rapid breathing, irritability, weakness, a headache, a high fever and others are the major symptoms of pneumococcal meningitis. Additionally, the development in the technology, innovation in the policies & strategies, establishment of new care centers has led to significant growth in the current scenario.
Pneumococcal Meningitis Overview
It is expected that in 2018 the Pneumococcal Meningitis disease hold the biggest share in the market. Whereas, with the significant growth in the market, the market of pneumococcal meningitis vaccine is segmented across the globe which includes Asia-Pacific region, Europe, North America, Middle east and Africa, Central and South America. Hence, the pneumococcal meningitis segment is intended to account for the most important share of the vaccines market in 2018. Nevertheless, North America is expected to account for the biggest share of the market whereas, Asia-Pacific region is also projected to dominate the highest share in the market and lead the market growth rate during the outlook period.
The Pneumococcal Meningitis can be communicated from one person to another through direct contact with the tiny droplets from an infected person’s mouth, nose, or throat. Not only this, disease can be transmitted by sharing anything such as a used cup, a straw, a lipstick, a cigarette, a fork and by kissing an infected person. Moreover, the treatment of pneumococcal meningitis infection can be done with the antibiotics but before the treatment some tests had to be done the respective doctor such as fluid testing which can be done through a spinal tap. Whereas, in the market several antibiotics are available with the easy availability of numerous antibiotics the market has become more competitive which result to significant growth. Therefore, the future of this industry is expected to be bright in the near future.
To know more, click on the link below:
Pneumococcal Meningitis Global Clinical Trials Review, H1, 2018
Related reports:
Pneumococcal Meningitis Global Clinical Trials Review, H2, 2016
Contact us:
Ken research
Ankur gupta, head marketing & communications
+91-9015378249
